RALUDOTATUG DERUXTECAN
UNII BPQ010OFD7

Substance Identification & Data

This profile provides standardized clinical and technical data for Raludotatug Deruxtecan, uniquely identified by the FDA Unique Ingredient Identifier (UNII) BPQ010OFD7.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2610074-57-0 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

BPQ010OFD7

CAS Registry Number

2610074-57-0

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

RALUDOTATUG DERUXTECAN

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C179214

National Cancer Institute reference terminology for clinical and research data.

INN ID

12314

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

NO-01

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Raludotatug Deruxtecan. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

RALUDOTATUG DERUXTECAN

Common Names & Synonyms

GAMMA1 HEAVY CHAIN HUMANIZED (1-452) (VH (HOMO SAPIENS IGHV1-3*01 (86.7%)-(IGHD)-IGHJ4*01(93.3%), CDR-IMGT (8.8.15) (26-33.51-58.97-111))(1-122) -HOMO SAPIENS IGHG1*03, G1M3, NG1M1 (CH1 R120 (219)(123-220), HINGE 1-15 (221-235), CH2 (236-345), CH3 E12 (361), M14 (363) (346-450), CHS (451-452)) (123-452)), (225-213')-DISULFIDE WITH KAPPA LIGHT CHAIN HUMANIZED (1'-213') (V-KAPPA (HOMO SAPIENS IGKV1-39*01 (86%) -IGKJ1*01 (91.7%), CDR-IMGT(6.3.8) (27-32.50-52.89-96)) (1'-106')-HOMO SAPIENS IGKC*01 (100%), KM3 A45.1 (152), V101(190) (107'-213')); DIMER (231-231'': 234-234'')-BISDISULFIDE, PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS, GLYCOFORM ALFA; CONJUGATED, ON AN AVERAGE OF 8 CYSTEINYL, TO DERUXTECAN, COMPRISING A LINKER AND A CAMPTOTHECIN DERIVATIVE

IMMUNOGLOBULIN G1, ANTI-(HUMAN G CADHERIN 6) (HUMAN-RATTUS NORVEGICUS MONOCLONAL MABU-9014A .GAMMA.1-CHAIN), COMPLEX WITH HUMAN-RATTUS NORVEGICUS MONOCLONAL MABU-9014A .KAPPA.-CHAIN, DIMER, OCTAKIS(THIOETHER) WITH N-(6-(3-MERCAPTO-2,5-DIOXO-1-PYRROLIDINYL)-1-OXOHEXYL)GLYCYLGLYCYL-L-PHENYLALANYL-N-((2-(((1S,9S)-9-ETHYL-5-FLUORO-2,3,9,10,13,15-HEXAHYDRO-9-HYDROXY-4-METHYL-10,13-DIOXO-1H,12H-BENZO(DE)PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLIN-1-YL)AMINO)-2-OXOETHOXY)METHYL)GLYCINAMIDE

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS CDH6(CADHERIN 6, K-CADHERIN (FOETAL KIDNEY), CADHERIN 6 TYPE 2)), HUMANIZED MONOCLONAL ANTIBODY CONJUGATED TO DERUXTECAN, COMPRISING A LINKER AND A CAMPTOTHECIN DERIVATIVE

RALUDOTATUG DERUXETCAN [USAN]

RALUDOTATUG DERUXTECAN [INN]

RALUDOTATUG DERUXTECAN [WHO-DD]